NM_000518.5:c.92+5G>C

Variant summary

Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong

The NM_000518.5(HBB):​c.92+5G>C variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000292 in 1,612,226 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: 𝑓 0.00024 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00030 ( 1 hom. )

Consequence

HBB
NM_000518.5 splice_region, intron

Scores

2
Splicing: ADA: 1.000
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:37O:1

Conservation

PhyloP100: 2.72
Variant links:
Genes affected
HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 8 ACMG points.

PP5
Variant 11-5226925-C-G is Pathogenic according to our data. Variant chr11-5226925-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 15447.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-5226925-C-G is described in Lovd as [Pathogenic]. Variant chr11-5226925-C-G is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
HBBNM_000518.5 linkc.92+5G>C splice_region_variant, intron_variant Intron 1 of 2 ENST00000335295.4 NP_000509.1 P68871D9YZU5

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
HBBENST00000335295.4 linkc.92+5G>C splice_region_variant, intron_variant Intron 1 of 2 1 NM_000518.5 ENSP00000333994.3 P68871

Frequencies

GnomAD3 genomes
AF:
0.000237
AC:
36
AN:
152190
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00726
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000593
AC:
149
AN:
251204
Hom.:
0
AF XY:
0.000803
AC XY:
109
AN XY:
135754
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00474
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000881
Gnomad OTH exome
AF:
0.000489
GnomAD4 exome
AF:
0.000297
AC:
433
AN:
1459918
Hom.:
1
Cov.:
33
AF XY:
0.000439
AC XY:
319
AN XY:
726420
show subpopulations
Gnomad4 AFR exome
AF:
0.0000598
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00471
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
9.01e-7
Gnomad4 OTH exome
AF:
0.000365
GnomAD4 genome
AF:
0.000243
AC:
37
AN:
152308
Hom.:
1
Cov.:
32
AF XY:
0.000389
AC XY:
29
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00747
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000288
Hom.:
0
Bravo
AF:
0.0000416
Asia WGS
AF:
0.00635
AC:
22
AN:
3478

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:37Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

beta Thalassemia Pathogenic:10Other:1
Apr 11, 2016
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: The c.92+5G>C variant affects a non-conserved intronic nucleotide. Mutation taster predicts damaging outcome for this variant. 4/5 programs in Alamut predict a loss of canonical splicing donor site. ESE finder predicts that this variant may affect ESE site of SC35. This variant is found in 87/121280 control chromosomes at a frequency of 0.0007173, which does not exceed maximal expected frequency of a pathogenic allele (0.0111803). This variant has been reported in many affected individuals (both homozygotes and compound heterozygotes with another disease variant in trans) presented with phenotypes including BTHAL-MJR and BTHAL-ITM. Functional studies proved the aberrant RNA splicing products (Treisman_Nature_1983). In addition, multiple reputable databases classified this variant as pathogenic. Taken together, this variant was classified as a Pathogenic. -

Nov 25, 2019
The ITHANET community portal, The Cyprus Institute of Neurology and Genetics
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: curation

- -

Mar 10, 2021
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Significance: Pathogenic
Review Status: flagged submission
Collection Method: clinical testing

- -

May 20, 2019
Natera, Inc.
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Nov 03, 2022
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.92+5G>C variant in HBB has been reported, in the homozygous and compound heterozygous state, in numerous individuals with beta thalassemia major and beta thalassemia intermedia (selected references Kazazian 1984 PMID: 6714226, Muhammad 2017 PMID: 28635337, https://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=824). It has been reported in ClinVar (Variation ID 15447) and has been identified in 35/4822 South Asian chromosomes by gnomAD (https://gnomad.broadinstitute.org). This variant is located in the 5' splice region. Computational tools predict a splicing impact and functional studies have shown it reduces or completelys deactivate the natural splice donor site in intron 1 and activates three cryptic splice donor sites (Treisman 1983 PMID: 6188062). Different splice variants at this residue (c.92+5G>A, c.92+5G>T) have been reported as pathogenic in ClinVar. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive beta thalassemia. ACMG/AMP Criteria applied: PM2_Supporting,PP3, PS3_Moderate, PM3_very strong. -

Dec 13, 2017
Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jul 22, 2021
Genome-Nilou Lab
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
GeneReviews
Significance: not provided
Review Status: no classification provided
Collection Method: literature only

- -

Sep 01, 2022
3billion, Medical Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.053%). Splice region variant. Functional studies provide moderate evidence that the variant has a damaging effect on the gene or gene product (PMID: 6188062). In silico tools predict the variant to alter splicing and produce an abnormal transcript (SpliceAI: 0.82). The homozygous variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000015447). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. -

-
Suma Genomics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 12, 2019
Myriad Genetics, Inc.
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

NM_000518.4(HBB):c.92+5G>C(aka IVS-I-5) is classified as pathogenic in the context of Hb beta chain-related hemoglobinopathy and is associated with beta thalessemia. Sources cited for classification include the following: PMID: 6714226, 6188062, 19000664, 18294253, and 23348723. Classification of NM_000518.4(HBB):c.92+5G>C(aka IVS-I-5) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -

not provided Pathogenic:10
Dec 17, 2022
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jun 28, 2022
Mayo Clinic Laboratories, Mayo Clinic
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Dec 22, 2021
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Reported in association with beta thalassemia major and beta thalassemia intermedia when in the homozygous or compound heterozygous state, opposite of a second HBB variant (Kazazian et al., 1984; Baysal, et al., 2011; Al-Allawi et al., 2013; Chaudhary et al., 2016).; Non-canonical splice site variant demonstrated to reduce or completely deactivate the natural splice donor site in intron 1 and activate three cryptic splice donor sites (Treisman et al., 1983; Divoky et al., 1992); Different splice variants at this residue (c.92+5G>A; c.92+5G>T) have been reported as pathogenic in ClinVar and at GeneDx (ClinVar SCV# 15449; 15448; ClinVar); This variant is associated with the following publications: (PMID: 6188062, 23348723, 22975760, 6585831, 31714438, 25525159, 1463768, 6714226, 23826747, 20301599, 22074124, 27134826, 23234478, 27690257, 20132300, 19000664, 18294253, 27263053, 2004023, 16291734, 14576320, 28635337, 29651865, 31589614, 31890591, 9163586) -

Nov 26, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The HBB c.92+5G>C variant (rs33915217, HbVar ID: 824), also known as IVS-I-5 (G->C), is reported in the literature in the homozygous and compound heterozygous state in multiple individuals affected with severe beta(+) thalassemia/ beta(0) thalassemia (Cheng 1984, Muhammad 2017, Panja 2016, Perea 2004, Yasmeen 2016, HbVar database and references therein). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 15447), and it is found in the South Asian population with an allele frequency of 0.47% (145/30,612 alleles) in the Genome Aggregation Database. Functional studies demonstrate that the variant causes aberrant splicing, leading to a significant reduction in full-length mRNA (Triesman 1983). Based on available information, the c.92+5G>C variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/hbvar.html Cheng T et al. Beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. Proc Natl Acad Sci U S A. 1984 81(9):2821-5. PMID: 6585831 Muhammad R et al. Population-Based Genetic Study of beta-Thalassemia Mutations in Mardan Division, Khyber Pakhtunkhwa Province, Pakistan. Hemoglobin. 2017 Mar;41(2):104-109. PMID: 28635337 Panja A et al. Hb Midnapore [beta53(D4)Ala?Val; HBB: c.161C>T]: A Novel Hemoglobin Variant with a Structural Abnormality Associated with IVS-I-5 (G>C) (HBB: c.92+5G>C) Found in a Bengali Indian Family. Hemoglobin. 2016 Sep;40(5):300-303. PMID: 27690257 Perea FJ Molecular spectrum of beta-thalassemia in the Mexican population. Blood Cells Mol Dis. 2004 Sep-Oct;33(2):150-2. PMID: 15315794 Treisman R et al. Specific transcription and RNA splicing defects in five cloned beta-thalassaemia genes. Nature. 1983 302(5909):591-6. PMID: 6188062 Yasmeen H et al. The molecular characterization of Beta globin gene in thalassemia patients reveals rare and a novel mutations in Pakistani population. Eur J Med Genet. 2016 Aug;59(8):355-62. PMID: 27263053 -

Jul 10, 2017
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 23, 2018
Eurofins Ntd Llc (ga)
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change falls in intron 1 of the HBB gene. It does not directly change the encoded amino acid sequence of the HBB protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs33915217, gnomAD 0.5%), and has an allele count higher than expected for a pathogenic variant. This variant has been observed in individuals with beta thalassemia (PMID: 18294253, 19000664, 22392582, 23162295, 27263053). It is commonly reported in individuals of Pakistani and Indian ancestry (PMID: 18294253, 19000664, 22392582, 23162295, 27263053). This variant is also known as IVS-I-5, IVSI-5, and IVS1-5. ClinVar contains an entry for this variant (Variation ID: 15447). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 6188062). For these reasons, this variant has been classified as Pathogenic. -

May 12, 2022
Revvity Omics, Revvity
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Jun 01, 2022
Clinical Genetics Laboratory, Skane University Hospital Lund
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

HBB: PM3:Very Strong, PM2:Supporting, PP3 -

Beta-thalassemia HBB/LCRB Pathogenic:6
-
Neuberg Centre For Genomic Medicine, NCGM
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The splice region c.92+5G>C variant in HBB gene has been reported previously in homozygous or compound heterozygous state in individual(s) affected with beta thalassemia (Yasmeen H et al., 2016). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (Treisman R et al., 1983). This variant is reported with the allele frequency of 0.05% in the gnomAD Exomes and novel in 1000 Genomes. This variant has been reported to the ClinVar database as Pathogenic by multiple submitters. This splice region variant in intron 1 affects the position five nucleotides downstream of exon 1. For these reasons, this variant has been classified as Pathogenic. In the absence of another reportable variant in HBB gene, the molecular diagnosis is not confirmed. -

May 07, 2024
MOLECULAR BIOLOGY AND HUMAN GENETICS DIVISION, THE UNIVERSITY OF BURDWAN
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The variant HBB:c.92+5G>C is beta zero type of mutation. When this variant present in homozygous or in compound heterozygous with other beta 0 / beta + mutation leads to severe anemia, The condition known as beta thalassemia. In homozygous condition the patient suffers with very low hemoglobin needing monthly transfusion, the patient often presented with hepatosplenomegaly, Iron overload. The frequency of the variant among thalassemia patient in Eastern India is 50.64 % as per our multicentric project - A Genetic Diagnostic Algorithm Based Study for Thalassemia in Northern and Eastern Indian Populations, Funded by Dept. of Biotechnology , Govt of India [Project No. BT/PR26461/MED/12/821/2018] -

-
Neuberg Centre For Genomic Medicine, NCGM
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The splice region c.92+5G>C variant in HBB gene has been reported in homozygous or compound heterozygous state in individuals affected with beta thalassemia (Yasmeen et al. 2016). The c.92+5G>C variant is reported with the allele frequency of 0.06% in the gnomAD Exomes. This variant has been reported to the ClinVar database as Pathogenic (multiple submissions). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing, and studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (Treisman et al. 1983). For these reasons, this variant has been classified as Pathogenic. In the absence of another reportable variant in the HBB gene, the molecular diagnosis is not confirmed. -

Oct 10, 2024
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Based on the classification scheme VCGS_Germline_v1.3.5, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with HBB-related hemoglobinopathies, including beta thalassemia (OMIM). Dominant negative is also a suggested mechanism (PMID: 29700171). (I) 0108 - This gene is associated with both recessive and dominant disease (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity. Variable severity has been reported in sickle cell patients carrying the same variants (PMID: 31788855). In addition, clinical severity of beta-thalassemia patients is also dependent on whether variants in HBB are heterozygous, homozygous or compound heterozygous, and the amount of residual protein that is expressed (PMID: 20301599). (I) 0209 - Splice site variant proven to affect splicing of the transcript with uncertain effect on protein sequence. This variant leads to the use of three cryptic splice sites, resulting in the formation of three abnormally spliced RNAs and a decreased amount of normally spliced RNA (PMID: 6188062). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 (v4: 466 heterozygotes, 2 homozygotes). (SP) 0309 - Multiple alternative amino acid changes at the same non-canonical splice position have been observed in gnomAD (v4) (highest allele count: 2 heterozygotes, 0 homozygotes). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as pathogenic by multiple clinical laboratories in ClinVar. This variant has also been observed in multiple unrelated homozygous and compound heterozygous individuals with beta-thalassemia, including at least four individuals who are compound heterozygous for this variant and p.(Ser10Valfs*14) (PMID: 27263053). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

-
Lifecell International Pvt. Ltd
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

A Homozygote Splice site region variant c.92+5G>C in Exon 1 of the HBB gene that results in the amino acid substitution was identified. The observed variant has a maximum allele frequency of 0.00059/0.00006% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score. Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic (variant ID: 15447). This variant has previously been reported for beta-thalassemia by Treisman R, et, al., 1983. Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines. -

Aug 09, 2022
MGZ Medical Genetics Center
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Beta-plus-thalassemia Pathogenic:2
Jan 01, 2018
College of Science, Al Muthanna University, Al Muthanna University
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: research

- -

May 01, 1984
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Dominant beta-thalassemia Pathogenic:1
Jul 22, 2023
Neuberg Centre For Genomic Medicine, NCGM
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The observed splice region c.92+5G>C variant in HBB gene has been reported in homozygous and compound heterozygous states in multiple individuals affected with beta thalassemia Panja et al., 2016; Yasmeen et al., 2016; Muhammad et al., 2017. Experimental Studies demonstrate that the variant causes aberrant splicing, leading to a significant reduction in full-length mRNA Treisman et al., 1983. The c.92+5G>C variant is present with the allele frequency of 0.06% in the gnomAD Exomes. This variant has been submitted to the ClinVar database as Pathogenic multiple submissions. SpliceAI predicts a score of 0.82 for this variant. Loss of function variants in HBB gene have been previously reported to be disease causing Aldakeel et al., 2019. For these reasons, this variant has been classified as Pathogenic. -

Inborn genetic diseases Pathogenic:1
Apr 13, 2017
Ambry Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.92+5G>C intronic pathogenic mutation results from a G to C substitution 5 nucleotides after coding exon 1 in the HBB gene. This mutation has been detected in individuals with beta-thalassemia (Agarwal S et al. Int J Lab Hematol, 2010 Jun;32:369-72; Sivalingam M et al. Int J Lab Hematol, 2012 Aug;34:377-82; Sirdah MM et al. Blood Cells Mol. Dis., 2013 Apr;50:247-51). In addition, this mutation showed reduced splicing efficiency with approximately half of the amount of RNA compared to wild type (Treisman R et al. Nature, 1983 Apr;302:591-6). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

HBB-related disorder Pathogenic:1
Apr 05, 2024
PreventionGenetics, part of Exact Sciences
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: clinical testing

The HBB c.92+5G>C variant is predicted to interfere with splicing. This variant is predicted to alter splicing based on available splicing prediction programs (Alamut Visual Pus v.1.6.1) and functional studies have shown aberrant splicing (Treisman et al. 1983. PubMed ID: 6188062). This variant has been reported in many affected individuals with Beta thalassemia (Treisman et al. 1983. PubMed ID: 6188062; Kazazian et al. 1984. PubMed ID: 6714226; Muhammad et al 2017. PubMed ID: 28635337; Susanto et al. 2019. PubMed ID: 31890591). This variant is reported in 0.47% of alleles in individuals of South Asian descent in gnomAD and is reported to be pathogenic by several other labs (https://www.ncbi.nlm.nih.gov/clinvar/variation/15447/). This variant is interpreted as pathogenic. -

alpha Thalassemia;C0002895:Hb SS disease;C0005283:beta Thalassemia;C0700299:Heinz body anemia;C1840779:METHEMOGLOBINEMIA, BETA TYPE;C1841621:Fetal hemoglobin quantitative trait locus 1;C1858990:Dominant beta-thalassemia;C1970028:Malaria, susceptibility to;C4693822:Erythrocytosis, familial, 6 Pathogenic:1
Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Malaria, susceptibility to Pathogenic:1
Mar 17, 2024
Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Centre
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

- -

Beta-thalassemia major Pathogenic:1
Feb 16, 2021
Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hb SS disease;C0019025:Hereditary persistence of fetal hemoglobin;C0700299:Heinz body anemia;C1840779:METHEMOGLOBINEMIA, BETA TYPE;C1858990:Dominant beta-thalassemia;C1970028:Malaria, susceptibility to;C4693822:Erythrocytosis, familial, 6;CN322236:Beta-thalassemia HBB/LCRB Pathogenic:1
Jun 17, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hb SS disease Pathogenic:1
-
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary persistence of fetal hemoglobin Pathogenic:1
-
Neuberg Centre For Genomic Medicine, NCGM
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The missense c.92+5G>C variant in HBB gene has been reported in heterozygous state in multiple individuals affected with Beta thalassemia (Hidayati NI, et. al., 2020; Yasmeen H,et. al., 2016). Functional studies demonstrate that the variant has a damaging effect on the gene or gene product (Treisman R, et. al.,1983). The c.92+5G>C variant is reported with an allele frequency of 0.05% in the gnomAD exomes database and is novel (not in any individuals) in 1000 Genomes database. This variant has been reported to the ClinVar database as Pathogenic (multiple submissions). For these reasons, this variant has been classified as Pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.43
CADD
Benign
20
DANN
Benign
0.73

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.99
SpliceAI score (max)
0.82
Details are displayed if max score is > 0.2
DS_DG_spliceai
0.43
Position offset: 21
DS_DL_spliceai
0.82
Position offset: 5

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs33915217; hg19: chr11-5248155; API